BRAF in non-small cell lung cancer

4 EU-approved indications in non-small cell lung cancer need a BRAF result: encorafenib (advanced), trametinib (advanced), dabrafenib (advanced) and binimetinib (advanced).

Line of therapy

Approved indications, Non-small cell lung cancer
DrugBiomarker requirementRegimenSettingConditions
BRAF mutation4
V600E
+ encorafenib
Any line
advanced
None
Dabrafenib
Tafinlar
V600
+ trametinib
Any line
advanced
None
Encorafenib
Braftovi
V600E
+ binimetinib
Any line
advanced
None
Trametinib
Mekinist
V600
+ dabrafenib
Any line
advanced
None

16 approvals for NSCLC need no biomarker and apply whatever the result. All approvals for NSCLC

See also

Label wording4

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Encorafenib (Braftovi)
    Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
  2. Trametinib (Mekinist)
    Trametinib in combination with dabrafenib is indicated for the treatment of adults with advanced non-small cell lung cancer with a BRAF V600 mutation.
  3. Dabrafenib (Tafinlar)
    Dabrafenib in combination with trametinib is indicated for the treatment of adults with advanced non-small cell lung cancer with a BRAF V600 mutation.
  4. Binimetinib (Mektovi)
    Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.